CLRB - 1.58 Pre-market now at 1.94/1.97 Cellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients http://stockcharts.com/c-sc/sc?s=CLRB&p=D&b=5&g=0&i=t26253353101&r=1502196448589 http://stockcharts.com/c-sc/sc?s=CLRB&p=W&b=5&g=0&i=t01272515725&r=1502196486564